MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards
MyGuava in association with Crystal Palace Football Club is thrilled to launch exclusive Crystal Palace Fan Cards with rewards and a variety of perks as well as a unique opportunity for fans to celebrate their connection to the club while enjoying MyGuava’s seamless payment solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101068560/en/
MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards (Photo: Business Wire)
Palace fans can now download the MyGuava App and order a Crystal Palace Card, choosing from three custom-designed cards: ‘Palace Gold’, ‘Palace Sash’ and ‘Selhurst 100’.
Each card comes packed with perks, including entry into exclusive prize draws, cashback on all purchases, giving Palace fans an opportunity to take advantage of the 7% cashback offer ahead of the festive period. Additionally, the cards come with Visa Platinum status for added financial flexibility.
Furthermore, for the most dedicated Eagles supporters, 900 limited-edition ‘Palace Gold’ cards will be available on a first come first served basis, offering enhanced cashback rates and special access to exclusive club benefits.
Rewards System
The MyGuava and Crystal Palace card will also be introducing a multi-stage reward system, providing cardholders with the exciting chance to earn Crystal Palace merchandise and experience based on spending. Supporters can win Crystal Palace branded bottles, t-shirts, hoodies as well as stadium tours and even personalised messages from the team for completing transaction milestones.
The MyGuava App, which is the flagship product of Guavapay, is designed to meet the broad financial needs of users. Users can open accounts in 20 currencies, make seamless local and global transfers, and use both virtual and physical debit cards. The App also has significant global reach, with access to 140 countries in more than 90 currencies and there are additional benefits with discounted gift cards from top brands and tools for enhancing user experience, such as digital skins, spending management tools and vaults.
To learn more about the Crystal Palace Card and Reward scheme, please visit the link below:
https://myguava.com/personal/landings/crystalpalace-cobrand-card
About Guavapay
Guavapay is a global fintech company with headquarters in London. The company has built a global financial ecosystem to empower individuals and businesses and give them more control over their financial lives. The All Things Payments App, MyGuava and the B2B platform, MyGuava Business simplify financial services, making them more accessible and affordable for people who have historically been overlooked.
The MyGuava Application is owned and operated by Guavapay Limited, a company registered in England with company number 10601900 and its registered address at Salisbury House, 29 Finsbury Circus, London, EC2M 5QQ, United Kingdom. Guavapay Limited is registered with the Financial Conduct Authority in the United Kingdom as a Small Electronic Money Institution with reference number 900888. Guavapay Limited’s ICO registration number is ZA274504.
For more information, please visit www.guavapay.com or contact:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101068560/en/
Contacts
Media Contacts:
Kieran McDonagh
Email - kieran.mcdonagh@guavapay.com
Rajeshwari Channakrishna
Email – rajeshwari.channakrishna@guavapay.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom